Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-α

Journal of Medical Virology

Volumn 83, Issue 11, 2011, Pages 2051-2055

  Javed, Saba ^a   Kamili, Qurat Ul Ain ^b   Mendoza, Natalia ^c   Tyring, Stephen K ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CENTER FOR CLINICAL STUDIES   (United States)

Author keywords

Herpes zoster; Postherpetic neuralgia; TNF inhibitor

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CROHN DISEASE; DISEASE ASSOCIATION; ETHNICITY; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; ISCHIALGIA; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PAIN; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; PSORIASIS; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HERPES ZOSTER; HUMANS; IMMUNOLOGIC FACTORS; INCIDENCE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

HERPES ZOSTER;

EID: 80052738296     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22182     Document Type: Article

References (23)

1. Coen PG, Scott F, Leedham-Green M, Nia T, Jamil A, Johnson RW, Breuer J. 2006. Predicting and preventing post-herpetic neuralgia: Are current risk factors useful in clinical practice? Eur J Pain 10:695-700.
2. Cohen SP, Wenzell D, Hurley RW, Kurihara C, Buckenmaier CC III, Griffith S, Larkin TM, Dahl E, Morlando BJ. 2007. A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. Anesthesiology 107:99-105.
3. Dahl E, Cohen SP. 2008. Perineural injection of etanercept as a treatment for postamputation pain. Clin J Pain 24:172-175.
4. Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, Patrick D, Camden S, Mansi JA. 2010. Predictors of postherpetic neuralgia among patients with herpes zoster: A prospective study. J Pain 11:1211-1221.
5. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. 2004. Practice parameter: Treatment of postherpetic neuralgia: An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 63:959-965.
6. Dworkin RH, Portenoy RK. 1996. Pain and its persistence in herpes zoster. Pain 67:241-251.
7. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. 2003. Advances in neuropathic pain: Diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60:1524-1534.
8. Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, Steck AJ. 2001. TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56:1371-1377.
9. Genevay S, Stingelin S, Gabay C. 2004. Efficacy of etanercept in the treatment of acute, severe sciatica: A pilot study. Ann Rheum Dis 63:1120-1123.
10. Jih JS, Chen YJ, Lin MW, Chen YC, Chen TJ, Huang YL, Chen CC, Lee DD, Chang YT, Wang WJ, Liu HN. 2009. Epidemiological features and costs of herpes zoster in Taiwan: A national study 2000 to 2006. Acta Derm Venereol 89:612-616.
11. Jung BF, Johnson RW, Griffin DR, Dworkin RH. 2004. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 62:1545-1551.
12. Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllonen E, Lindgren KA, Rantanen P, Tervonen O, Niinimaki J, Seitsalo S, Hurri H. 2003. Tumor necrosis factor-alpha monoclonal antibody, infliximab, used to manage severe sciatica. Spine (PhilaPa 1976) 28:750-753, discussion 753-754.
13. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ. 2003. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 188:1336-1344.
14. Opstelten W, Mauritz JW, de Wit NJ, van Wijck AJ, Stalman WA, van Essen GA. 2002. Herpes zoster and postherpetic neuralgia: Incidence and risk indicators using a general practice research database. Fam Pract 19:471-475.
15. Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, Verheij TJ, Moons KG. 2007. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 132 (Suppl 1): S52-S59.
16. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB. 2002. Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 59:1015-1021.
17. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. 2006. The burden of herpes zoster: A prospective population based study. Vaccine 24:1308-1314.
18. Sorkin LS, Doom CM. 2000. Epineurial application of TNF elicits an acute mechanical hyperalgesia in the awake rat. J Peripher Nerv Syst 5:96-100.
19. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. 2009. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301:737-744.
20. Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. 2007. Natural history of pain following herpes zoster. Pain 128:148-156.
21. Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. 2008. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 80:1646-1652.
22. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. 2007. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 82:1341-1349.
23. Zhu SM, Liu YM, An ED, Chen QL. 2009. Influence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgia. J Zhejiang Univ Sci B 10:625-630.